Oncolytics Biotech: Focusing its Trials

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Oncolytics Biotech: Focusing its Trials
Released on: February 24, 2009. © PharmaVentures Ltd
Share/save this page:
Follow us:
In This Episode:
  • Summary
  • Participants
  • Company
Dr. Brad Thompson, CEO of Oncolytics Biotech talks through the solid science that underpins his company. Whilst describing the company’s story to date he discusses overcoming the regulatory hurdles and perceptual issues of injecting a live virus into a subject during trials and how they expect to dramatically narrow their twelve clinical trials down to two pivotal programmes during 2009. Whilst the company currently funds the trials alone without any big pharma collaborations Dr. Thompson suggests that this may change as the year progresses.
Brad Thompson
Chairman, President and CEO
Oncolytics Biotech Inc.

Dr. Thompson has provided leadership to various organizations within the biotechnology sector for more than 20 years. Prior to becoming Chairman, President and CEO of Oncolytics, he held a number of senior executive positions with SYNSORB Biotech from 1994 to 1999.

From 1983 to 1994, Dr. Thompson worked in a senior role at The Alberta Research Council. He received his Ph.D. from the University of Western Ontario in the Department of Microbiology and Immunology.
Oncolytics Biotech Inc.